Recent studies have centered on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor agonist therapies and dopaminergic neurotransmission. While GCGR agonists are commonly employed for treating type 2 T2DM, their unexpected impacts on motivation circuits, specifically governed by dopaminergic networks, are receiving … Read More